Anti-Human CD274 Recombinant Antibody (Durvalumab) (CAT#: TAB-417CQ)

Figure 1 Monalizumab and Durvalumab Unleash NK and CD8 + T Cell Function In Vitro.

NK cells were co-cultured with K562 or K562 cells expressing HLA-E in the presence or absence of monalizumab. The frequencies of CD107-positive NK cells are shown. Box and whiskers plot, with the means indicated by crosses. N = 8. The whiskers are drawn down to the 25th percentile minus 1.5 times IQR (interquartile range) and up to the 75th percentile plus 1.5 times IQR. Friedman analysis followed by Dunn's multiple comparisons test. **p = 0.006; ***p = 0.0001.

André, P., Denis, C., Soulas, C., Bourbon-Caillet, C., Lopez, J., Arnoux, T.,... & Rossi, B. (2018). Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell, 175(7), 1731-1743.

Figure 1 Anti-Human CD274 Antibody (TAB-417CQ) in ELISA

ELISA analysis of TAB-417CQ was performed by coating with PD-L1 Protein, Human, Recombinant (His Tag).
The secondary antibody: HRP-Anti-Human IgG (H+L)

Figure 2 Anti-Human CD274 Antibody (TAB-417CQ) in WB

Western blot analysis of TAB-417CQ was performed with PD-L1 Protein, Human, Recombinant (His Tag).
TAB-417CQ incubation concentration: 2ng/μL.
The secondary antibody: HRP-Anti-Human IgG (H+L)
Lane 1: Reducing antigen (0.1μg)
Lane 2: Reducing antigen (0.3μg)
Lane 3: Reducing antigen (0.6μg)

Figure 3 Anti-Human CD274 Antibody (TAB-417CQ) in DB

Dot blot analysis of TAB-417CQ was performed with PD-L1 Protein, Human, Recombinant (His Tag).
TAB-417CQ incubation concentration: 2ng/μL.
NC: Negative control PC: Positive control